|
Value |
Females /males, n (TDM samples) |
130 (272) / 185 (399) |
Age, years, mean (95%CI)a
|
24.9 (23.3,
26.4) |
Prop. of samples with sampling time, n (n patients) |
232
(148) |
Sampling time, hours, mean (95%CI)a
|
5.4 (5.2,
5.6) |
Prop. of samples with dose, n (n patients) |
587 (274) |
Dose, mg, mean (95%CI)a
|
53.4 (49.7,
57.2) |
Prop. of undetectable serum samples (n patients) |
80
(68) |
Atomoxetine serum conc., nM, mean (95%CI)a
|
1385
(1194, 1577) |
CYP2D6 genotype subgroups, n
UM / NM / IM / PM
|
4 / 163 / 116 / 32
|
CYP2C19*2 carriers / non-carriers |
109 / 206 |
aThe means were calculated with linear mixed model
with no covariates.
TDM, therapeutic drug monitoring; Sampling time, time between last dose
and blood sampling; CYP, cytochrome P450; UM, ultra-rapid metabolizers;
NM, normal metabolizers; IM, intermediate metabolizers; PM, poor
metabolizers; CI, confidence intervals.
|
aThe means were calculated with linear mixed model
with no covariates.
TDM, therapeutic drug monitoring; Sampling time, time between last dose
and blood sampling; CYP, cytochrome P450; UM, ultra-rapid metabolizers;
NM, normal metabolizers; IM, intermediate metabolizers; PM, poor
metabolizers; CI, confidence intervals.
|